drugset / Trial / NCT03232177
Anagre Cap. in Patients With High-Risk Essential Thrombocythemia
NaSingle-groupOpen-labelTreatment
Summary
This study is to evaluate the efficacy and safety according to incremental dosing for 8 weeks and duration of administration for 1 year in patients with high-risk essential thrombocythemia.
Timeline
- Start
- 2017-06-05
- Primary completion
- 2020-12-05
- Completion
- 2020-12-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anagrelide | Small molecule | 10 mg | — |